IFIT2 and breast cancer: The lncRNA H19, for example, confers cisplatin resistance in high-grade advanced ovarian tumours [11], Overexpression of the lncRNA LINC00161 enhanced cisplatin-induced apoptosis in osteosarcoma cells by modulating the miR-645-IFIT2 axis [12], the lncRNA SLC25A25-AS1 has been reported to mediate drug resistance and EMT in colorectal cancer cells [9], and linc-ROR exhibited impaired sensitivity to 5-FU in breast cancer cells [13].